ACBD5 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ACBD5 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AFAP1L2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AFAP1L2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 2.92% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

ARAF is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 36.62% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 5 clinical trials for thyroid gland undifferentiated (anaplastic) carcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRAF status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [3].

Dabrafenib and trametinib have evidence of efficacy in patients with BRAF mutation in thyroid gland undifferentiated (anaplastic) carcinoma [3].

CCDC6 is altered in 1.87% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

CCDC6 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCDC6 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CEP43 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEP43 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is altered in 1.8% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERC1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERC1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

GOLGA5 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains GOLGA5 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HOOK3 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HOOK3 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is altered in 4.35% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIAA1217 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIAA1217 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIF5B is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIF5B status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 2.11% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for thyroid gland undifferentiated (anaplastic) carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K4 is altered in 0.82% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP3K1 is altered in 1.72% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK1 is altered in 0.88% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NCOA4 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NCOA4 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NF1 is altered in 11.81% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NF2 is altered in 11.29% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

NF2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is altered in 19.86% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPFIBP2 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPFIBP2 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PRKAR1A is altered in 0.88% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

PRKAR1A is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PRKAR1A status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 1.41% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RUFY1 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RUFY1 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SRC is altered in 1.54% of thyroid gland undifferentiated (anaplastic) carcinoma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TFG is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TFG status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TRIM27 is an inclusion eligibility criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRIM27 status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].